NCT05949203View on ClinicalTrials.gov

Oregon PrEP at Home Study

RecruitingOBSERVATIONAL

Enrollment

125

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions

HIV/AIDS

Interventions

DRUG

Cabotegravir Injection

Administration of HIV pre-exposure prophylaxis with cabotegravir 600 mg/3mL extended release injectable suspension every other month.

Trial Locations (1)

97239

RECRUITING

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

ViiV Healthcare

INDUSTRY

lead

Oregon Health and Science University

OTHER